P5178

Phenobarbital sodium salt

• Sinónimos: 5-Ethyl-5-phenyl-2,4,6-trioxohexahydropyrimidine sodium salt, 5-Ethyl-5-phenylbarbituric acid sodium salt, Luminal sodium salt, Sodium 5-ethyl-5-phenylbarbiturate
• Fórmula empírica (notación de Hill): C₁₂H₁₁N₂NaO₃
• Número de CAS: 57-30-7
• Peso molecular: 254.22
• Beilstein: 3802044
• Número CE: 200-322-3
• Número MDL: MFCD00036211
• Código UNSPSC: 12352202
• ID de la sustancia en PubChem: 24898608
• NACRES: NA.77

Propiedades

• Formulario: powder
• Nivel de calidad: 200
• control farmacológico: USDEA Schedule IV; Home Office Schedule 3; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)
• solubilidad: H₂O: 1 g/mL; ethanol: 100 mg/mL
• emisor: Bayer
• cadena SMILES: [Na+].CCC1(C(=O)NC([O-])=NC1=O)c2ccccc2
• InChI: 1S/C12H12N2O3.Na/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;/h3-7H,2H2,1H3,(H2,13,14,15,16,17);/q;+1/p-1
• Clave InChI: WRLGYAWRGXKSKG-UHFFFAOYSA-M

Descripción

Aplicación

Phenobarbital sodium salt has been used:

• to anesthetize mice for inducing ischemia-reperfusion injury[1]
• as a positive control for the activation of constitutive androstane receptor (CAR)[2]
• in bioluminescent yeast bioreporters (BLYAS) assay[3]

Acciones bioquímicas o fisiológicas

Phenobarbital, a substituted barbituric acid is an antileptic drug and is not easily eliminated from circulation.[4] It hyperpolarizes the synaptic neuronal membranes by favoring the activation of neuronal postsynaptic GABAA receptors by γ aminobutyric acid (GABA). Phenobarbital is also effective in treating neonatal seizures and status epilepticus.[5]

Sedative; hypnotic; anticonvulsant; enhances GABAergic activity.

Características y beneficios

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Dopamine and Norepinephrine Metabolism and GABAA Receptors pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Pictogramas: GHS06,GHS08
• Palabra de señalización: Danger
• Frases de peligro: H301,H317,H351
• Consejos de prudencia: P202 - P261 - P264 - P280 - P301 + P310 - P302 + P352
• Clasificaciones de peligro: Acute Tox. 3 Oral - Carc. 2 - Skin Sens. 1
• Código de clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable
• Equipo de protección personal: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges